Xenotherapeutics Enters the Sector With a Patent Application Related to Xenotransplantation
Xenotherapeutics is a clinical-stage biotechnology research and development company. The company is focused on developing personalized cells, tissues, and organs to provide regenerative medicine solutions. Specifically, the company is interested in xenotransplantation which involves the transplantation of living cells, tissues, or organs from one species to another. The company is best known for its Xeno-Skin®. It is a genetically engineered xenotransplantation skin product for preventing infection, preventing fluid loss, and restoring the epidermal barrier prior to wound closure.
In relation to this, a patent application assigned to Xenotherapeutics was published on December 12, 2021 for selection and monitoring methods for xenotransplantation. The application discusses the use of AI for predicting the performance of a sample, when the sample is derived from a genetically optimized non-human donor. As it does not appear that any competitors in the sector have a similar patent at this time, we can expect that Xenotherapeutics will continue to file to protect these methods.
To keep an eye on Xenotherapeutics and other innovative companies check out the AI Biotech Patent Forecast®!
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…